Bayer AG, Onyx Pharmaceuticals, Inc.'s Regorafenib Meets Key Endpoint

Published: Oct 28, 2011

Germany's Bayer AG (BAYN.XE) Wednesday said its Phase III trial evaluating its investigational compound regorafenib for the treatment of patients with metastatic colorectal cancer has met its primary endpoint in significantly improving overall survival. Main facts: -The trial was stopped ahead of schedule based on the positive data from a pre-planned interim analysis. -The data are based on the analysis of the CORRECT trial on patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy.

Back to news